CDC releases basic safety data on rotavirus vaccine RotaTeq The Centers for Disease Control and Prevention released today new safety data on a recently licensed rotavirus vaccine directed at infants that indicate the vaccine will not pose an elevated risk for intussusception, the most typical reason behind bowel obstruction in infants. The vaccine, sold by Merck and Company beneath the brand name RotaTeq, was certified by the U.S. Food and Medication Administration in February 2006. The Advisory Committee on Immunization Procedures recommends RotaTeq for routine vaccination of U.S. Infants to protect against rotavirus, which causes severe diarrhea, vomiting, fever and dehydration in kids.Outcomes showed that kids who had been subjected to the adenovirus 36 were more likely to become obese than kids who were never infected, with 22 % of obese children having antibodies to the virus, in comparison to 7 % of normal-weight children. These antibodies are indicative of the fact that the body’s disease fighting capability has tried to guard itself against the virus, an indicator of prior exposure or infection. Mean pounds in those who carried antibodies to the virus was 92.9 kg, compared with 69.1 kg in those who were antibody-unfavorable. Adults studied in other studies have shown similar outcomes. On the flip side 4 of the 19 children in the new study who carried antibodies weren’t overweight.